{"protocolSection": {"identificationModule": {"nctId": "NCT01598740", "orgStudyIdInfo": {"id": "CTST-25"}, "organization": {"fullName": "Sorbent Therapeutics", "class": "INDUSTRY"}, "briefTitle": "Evaluation of CLP With and Without Spironolactone in Heart Failure Patients With Chronic Kidney Disease", "officialTitle": "A Phase 1, Open-label, Randomized, Crossover Study to Assess the Safety, Tolerability, and Efficacy of CLP With and Without Spironolactone in Adults With Heart Failure"}, "statusModule": {"statusVerifiedDate": "2013-07", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2012-06"}, "primaryCompletionDateStruct": {"date": "2012-09", "type": "ACTUAL"}, "completionDateStruct": {"date": "2012-09", "type": "ACTUAL"}, "studyFirstSubmitDate": "2012-05-11", "studyFirstSubmitQcDate": "2012-05-11", "studyFirstPostDateStruct": {"date": "2012-05-15", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2013-03-22", "resultsFirstSubmitQcDate": "2013-03-22", "resultsFirstPostDateStruct": {"date": "2013-05-08", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2013-07-12", "lastUpdatePostDateStruct": {"date": "2013-07-19", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Sorbent Therapeutics", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The purpose of this study is to determine the effects of CLP, with and without spironolactone, on serum, urine, and fecal contents in heart failure patients with chronic kidney disease."}, "conditionsModule": {"conditions": ["Heart Failure"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "CROSSOVER", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 18, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "CLP with spironolactone", "type": "EXPERIMENTAL", "interventionNames": ["Drug: CLP", "Drug: Spironolactone"]}, {"label": "CLP without spironolactone", "type": "EXPERIMENTAL", "interventionNames": ["Drug: CLP"]}], "interventions": [{"type": "DRUG", "name": "CLP", "description": "Oral administration", "armGroupLabels": ["CLP with spironolactone", "CLP without spironolactone"]}, {"type": "DRUG", "name": "Spironolactone", "description": "oral administration", "armGroupLabels": ["CLP with spironolactone"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change in Fecal Sodium Content", "description": "Change =(Days 10-13/29-32 Daily Average)-(Days 3-6/22-25 Daily Average)", "timeFrame": "baseline average (days 3-6 or days 22-25) and treatment average (days 10-13 or 29-32)"}], "secondaryOutcomes": [{"measure": "Change in Fecal Weight", "description": "Change = (Days 10-13/29-32 Daily Average) - (Days 3-6/22-25 Daily Average)", "timeFrame": "baseline average (days 3-6 or 22-25) and treatment average (days 10-13 or 29-32)"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Heart failure with New York Heart Association (NYHA) Classification II or III\n* Chronic kidney disease\n* Cardiac ejection fraction \\<40%\n* On heart failure therapy including an ACEI or ARB, and a BB\n* Willing to understand and comply with study procedures and provide written informed consent.\n\nExclusion Criteria:\n\n* Hospitalization within 4 weeks of baseline visit\n* History or presence of gastrointestinal conditions such as severe constipation or gastrointestinal tract strictures\n* Current or anticipated dialysis during study\n* In the investigator's judgment, any cardiovascular, renal, hepatic, endocrine, gastrointestinal, neurological, or other disease or condition that makes the subject's study participation unsafe\n* Drug or alcohol abuse", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Howard Dittrich, MD", "affiliation": "Sorbent Therapeutics, Study Sponsor", "role": "STUDY_CHAIR"}, {"name": "Joel Neutel, MD", "affiliation": "Orange County Research Center", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Orange Country Research Center", "city": "Tustin", "state": "California", "zip": "92780", "country": "United States", "geoPoint": {"lat": 33.74585, "lon": -117.82617}}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Each study period included a 5-day baseline period followed by a 7-day treatment period. The study periods were separated by a 7-day washout period.", "recruitmentDetails": "The first subject was enrolled on 01 June 2012 and the last subject completed on 06 August 2012. The study was completed at one research center.", "groups": [{"id": "FG000", "title": "CLP + Spiro (7 Days), Washout (7 Days), CLP (7 Days)", "description": "Subjects in this group received coadministration of CLP orally and spironolactone orally in Period 1/administration of CLP orally alone in Period 2."}, {"id": "FG001", "title": "CLP (7 Days), Washout (7 Days), CLP + Spiro (7 Days)", "description": "Subjects in this group received administration of CLP alone orally in Period 1/coadministration of CLP orally and spironolactone orally in Period 2."}], "periods": [{"title": "Period 1", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "9"}, {"groupId": "FG001", "numSubjects": "9"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "9"}, {"groupId": "FG001", "numSubjects": "9"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}]}]}, {"title": "Period 2", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "comment": "1 subject discontinued during the washout period prior to starting treatment period 2.", "numSubjects": "8"}, {"groupId": "FG001", "numSubjects": "9"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "7"}, {"groupId": "FG001", "numSubjects": "9"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "CLP + Spiro/CLP", "description": "Subjects in this group received coadministration of CLP orally and spironolactone orally in Period 1/administration of CLP orally alone in Period 2."}, {"id": "BG001", "title": "CLP/CLP + Spiro", "description": "Subjects in this group received administration of CLP alone orally in Period 1/coadministration of CLP orally and spironolactone orally in Period 2."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "9"}, {"groupId": "BG001", "value": "9"}, {"groupId": "BG002", "value": "18"}]}], "measures": [{"title": "Age Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "56.3", "spread": "7.58"}, {"groupId": "BG001", "value": "63.4", "spread": "9.77"}, {"groupId": "BG002", "value": "59.9", "spread": "8.7"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "4"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "5"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "8"}, {"groupId": "BG002", "value": "13"}]}]}]}, {"title": "Weight", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kg", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "91.35", "spread": "24.20"}, {"groupId": "BG001", "value": "99.54", "spread": "27.49"}, {"groupId": "BG002", "value": "95.4", "spread": "25.8"}]}]}]}, {"title": "Diet", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Low sodium", "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "3"}]}]}, {"title": "Medium sodium", "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "2"}]}]}, {"title": "High sodium", "categories": [{"measurements": [{"groupId": "BG000", "value": "7"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG002", "value": "13"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change in Fecal Sodium Content", "description": "Change =(Days 10-13/29-32 Daily Average)-(Days 3-6/22-25 Daily Average)", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mg", "timeFrame": "baseline average (days 3-6 or days 22-25) and treatment average (days 10-13 or 29-32)", "groups": [{"id": "OG000", "title": "Treatment Group: CLP Alone", "description": "oral administration"}, {"id": "OG001", "title": "Treatment Group: CLP + Spironolactone", "description": "CLP: oral administration Spironolactone: oral administration"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "16"}, {"groupId": "OG001", "value": "18"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "635.10", "spread": "441.11"}, {"groupId": "OG001", "value": "501.95", "spread": "342.52"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "One-way analysis of covariance (ANCOVA) common slopes model for a 2-period crossover design.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0662", "statisticalMethod": "ANCOVA", "ciPctValue": "95"}]}, {"type": "SECONDARY", "title": "Change in Fecal Weight", "description": "Change = (Days 10-13/29-32 Daily Average) - (Days 3-6/22-25 Daily Average)", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "grams", "timeFrame": "baseline average (days 3-6 or 22-25) and treatment average (days 10-13 or 29-32)", "groups": [{"id": "OG000", "title": "Treatment Group: CLP Alone", "description": "CLP: oral administration"}, {"id": "OG001", "title": "Treatment Group: CLP + Spironolactone", "description": "CLP: oral administration Spironolactone: oral administration"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "16"}, {"groupId": "OG001", "value": "18"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "144.7", "spread": "86.50"}, {"groupId": "OG001", "value": "119.0", "spread": "106.98"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "One-way analysis of covariance (ANCOVA) common slopes model for a 2-period crossover design.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.1899", "statisticalMethod": "ANCOVA", "ciPctValue": "95"}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "eventGroups": [{"id": "EG000", "title": "Treatment Group: CLP Alone", "description": "oral administration", "seriousNumAffected": 0, "seriousNumAtRisk": 16, "otherNumAffected": 5, "otherNumAtRisk": 16}, {"id": "EG001", "title": "Treatment Group: CLP + Spironolactone", "description": "CLP: oral administration Spironolactone: oral administration", "seriousNumAffected": 0, "seriousNumAtRisk": 18, "otherNumAffected": 8, "otherNumAtRisk": 18}], "otherEvents": [{"term": "Abdominal distension", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 9.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 18}]}, {"term": "Abdominal pain upper", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 9.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 18}]}, {"term": "Constipation", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 9.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 18}]}, {"term": "Dyspepsia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 9.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 18}]}, {"term": "Asthenia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 9.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 18}]}, {"term": "Fatigue", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 9.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 18}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 9.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 18}]}, {"term": "Hypovolaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 9.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 18}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 9.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 18}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 9.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 18}]}, {"term": "Anxiety", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 9.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 18}]}, {"term": "Pulmonary Congestion", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 9.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 18}]}, {"term": "Cold sweat", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 9.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 18}]}, {"term": "Hypotenstion", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 9.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 18}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true}, "pointOfContact": {"title": "Howard Dittrich, MD", "organization": "Sorbent Therapeutics, Inc.", "email": "hdittrich@sorbent.com", "phone": "858-405-1429"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000006333", "term": "Heart Failure"}], "ancestors": [{"id": "D000006331", "term": "Heart Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M10698", "name": "Kidney Diseases", "relevance": "LOW"}, {"id": "M9421", "name": "Heart Failure", "asFound": "Heart Failure", "relevance": "HIGH"}, {"id": "M9419", "name": "Heart Diseases", "relevance": "LOW"}, {"id": "T1303", "name": "Chronic Graft Versus Host Disease", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BXS", "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000013148", "term": "Spironolactone"}], "ancestors": [{"id": "D000000451", "term": "Mineralocorticoid Receptor Antagonists"}, {"id": "D000006727", "term": "Hormone Antagonists"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000062865", "term": "Diuretics, Potassium Sparing"}, {"id": "D000004232", "term": "Diuretics"}, {"id": "D000045283", "term": "Natriuretic Agents"}], "browseLeaves": [{"id": "M15943", "name": "Spironolactone", "asFound": "Estradiol", "relevance": "HIGH"}, {"id": "M3797", "name": "Mineralocorticoid Receptor Antagonists", "relevance": "LOW"}, {"id": "M11871", "name": "Mineralocorticoids", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}, {"id": "M7411", "name": "Diuretics", "relevance": "LOW"}, {"id": "M30025", "name": "Diuretics, Potassium Sparing", "relevance": "LOW"}], "browseBranches": [{"abbrev": "NaAg", "name": "Natriuretic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}